A world leader in genomics, but England’s patients face obstacles to tests
England is at the forefront of the genomics revolution – but NHS patients are unlikely to be the first to benefit.
England is at the forefront of the genomics revolution – but NHS patients are unlikely to be the first to benefit.
Axovant misreports trial results, Lundbeck Alzheimer’s drug fails
Walmsley has axed 40% of management team in shake-up